

FDA clears the way for PHILAB

The Food and Drug Administration (FDA) grants Philab Industries two (2) licenses to operate which covers drugs, vaccines, biologics and medical devices. The FDA which imposes strict requirements for the issuance and maintenance of such license has allowed Philab to apply for a market authorization for health products prior to manufacture, importation, sale or offer for sale, distribution, transfer, advertisement and/or promotion.

One of Philab test kit products is the LABit Dx Dengue NS1 Ag self-test kit which can be used as early as the onset of fever and can produce results in just 15 minutes.

Philab recently launched its Dengue Awareness Campaign to strengthen efforts towards a proactive mindset in responding to diseases through the use of the screening tool. Philab teamed up with Healthway Medical, the most trusted and preferred brand for mall-based medical clinics in the Philippines to give full attention to one of the potentially deadly diseases, dengue. The LABit Dx dengue self-test kits will help doctors cut down time in diagnosis and curb the mortality rate of dengue infection.



Philab through its brand LABit Dx, will provide the Dengue NS1 Ag self-test kit to the clinics. This collaboration will enable Healthway to expand its businesses to early screening of dengue infection and advocate for a better understanding of the disease. The Philab launched the self-test kits in March of this year and is currently available on lazada.com.ph. LABit is a brand owned by Philab Holdings Corp. (PSE ticker symbol: DNA). Website: philab.com